Immune thrombocytopenia (ITP) comprises a heterogeneous group of disorders characterized by autoimmune-mediated platelet destruction and impairment of thrombopoiesis. ITP may occur in the absence of an evident predisposing etiology (primary ITP) or secondary to a growing list of associated conditions (secondary ITP), and must be differentiated from other causes of thrombocytopenia. This review focuses on primary ITP in adults. The traditional goal of therapy in this population is to achieve a hemostatic platelet count of 30 × 109/L or above for most patients while minimizing treatment-related morbidity. This approach has been called into question by the recent advent of well-tolerated and effective agents for the management of ITP, including pulse-dose dexamethasone, rituximab, and the thrombopoietin receptor agonists. Recent studies suggest the potential for aggressive therapy at the time of diagnosis to alter the natural history of ITP and point to the importance of quality-of-life considerations in therapeutic decision making.

Immune thrombocytopenia (ITP) is an autoimmune syndrome involving antibody- and cell-mediated destruction of platelets and suppression of platelet production that may predispose to bleeding.1  Recent recommendations from an international working group suggest that ITP be used to designate all cases of immune-mediated thrombocytopenia, whether occurring as a component of another clinically evident disorder or drug exposure (secondary ITP) or in the absence of a clear predisposing etiology (primary ITP).2,3  The international working group also recommends that a platelet count below 100 × 109/L, rather than 150 × 109/L, be required for diagnosis. This threshold is based on observational evidence that fewer than 10% of otherwise healthy individuals with a stable platelet count between 100 and 150 × 109/L develop more severe unexplained ITP over the ensuing 10 years.4  This review focuses on primary ITP in the adult population, but includes certain aspects of secondary forms and pediatric ITP where pertinent. The management of ITP in pregnancy is discussed elsewhere in this issue (see “Thrombocytopenia in Pregnancy”).

Estimates of the incidence of adult-onset ITP range from approximately 1.6 to 3.9 per 100,000 persons per year, with a prevalence ranging from 9.5 to 23.6 per 100,000 persons, based on diagnostic codes in the UK health registry5,6 ; estimates based on International Classification of Diseases, 9th revision (ICD-9) codes at hospital discharge in the United States are somewhat lower.7  However, in light of the vagaries of diagnosis and diagnostic coding, as well as the likelihood that some affected patients may not seek medical attention, the actual frequency of ITP and the number of individuals requiring therapy is uncertain.

Adult-onset ITP was once believed to be a disease largely afflicting young women. Indeed, several recent studies confirm a female preponderance in young adults, but surprisingly, they also highlight a much higher prevalence among older individuals in whom males and females appear to be equally affected.5,6  It is not known whether these findings reflect an evolution in disease epidemiology or merely a shift in the way clinicians ascertain and diagnose ITP.

The underlying defects leading to autoantibody production are unknown. Heritability is uncommon,8  although predisposing polymorphisms in cytokines and Fcγ receptors have been described. A Th1/Th0 cytokine profile,9  a reduction in suppressor T-regulatory cells,10  and an increase in B-cell-activating factor11  may predispose to emergence of autoantibodies in response to exogenous antigens.12  Molecular mimicry appears to play a role in the development of self-reactive platelet antibodies after vaccination and certain viral infections. For example, antibodies to microbial (viral and bacterial) antigens that cross-react with platelets, often an epitope within glycoprotein IIIa, have been identified in patients who develop ITP in association with HIV, hepatitis C virus, and Helicobacter pylori infection.13–15  In support of this postulated mechanism, microbial reduction/eradication leads to remission in a substantial fraction of infected patients, although questions remain regarding how platelet-reactive autoantibodies develop and, in the case of H. pylori, why there appears to be marked variations in response rates among patients from different parts of the world.16  The mechanisms leading to autoantibody production may differ in secondary forms of ITP associated with immunosuppression or immune dysregulation.1 

Platelet life span is reduced as a consequence of antibody-mediated clearance by tissue macrophages in essentially all patients. Accumulating evidence from studies of platelet kinetics also points to the contribution of immune-mediated suppression of megakaryocyte and platelet development in many patients17 ; megakaryocyte apoptosis18  and suppression of megakaryopoiesis in vitro by ITP plasma/immunoglobulin G (IgG)19  or T-cells20 ; and responsiveness to thrombopoietin receptor agonists (TRAs).21–23  Direct peroxide-induced, antibody-mediated lysis of platelets has been reported in ITP associated with HIV.24  Platelet-reactive antibodies are not detected in all individuals with ITP, and a subset of patients do not respond to pharmacologic or surgical inhibition of antibody-mediated platelet clearance or B-cell suppression, suggesting the possible involvement of other pathogenic mechanisms such as antibody-mediated apoptosis, antigen shedding, and T-cell mediated platelet destruction or marrow suppression.25 

Primary ITP remains a diagnosis of exclusion from both non-autoimmune causes (Table 1) and secondary causes (Figure 1) of ITP. In particular, congenital thrombocytopenias must be borne in mind in the evaluation of isolated thrombocytopenia, because differentiation from ITP can be quite difficult without historical platelet counts from the patient and study of family members. Secondary causes are estimated to comprise approximately 20% of cases of ITP in the United States, and possibly a higher percentage in regions where predisposing infections are more prevalent1  (Figure 1). Recommendations from a recent international consensus conference for the initial evaluation of primary ITP are shown in Table 2.2,3  These recommendations do not take into consideration the regional variation in response of ITP to antimicrobial therapy (e.g., the low incidence of an ITP response in the United States after eradication of H. pylori), nor the cost-effectiveness of testing in the absence of a pertinent clinical history (e.g., measuring immunoglobulin levels in all patients). Response to ITP-specific therapy remains the single most compelling diagnostic criterion.

Figure 1.

Estimated fraction of the various forms of ITP based on clinical experience of the authors. (From Cines et al., 2009.1  Used with permission.) SLE, systemic lupus erythematosus; APS, antiphospholipid syndrome; CVID, common variable immune deficiency; CLL, chronic lymphocytic leukemia; APLS, autoimmune lymphoproliferative syndrome; post-tx, post-bone marrow or solid organ transplantation

Figure 1.

Estimated fraction of the various forms of ITP based on clinical experience of the authors. (From Cines et al., 2009.1  Used with permission.) SLE, systemic lupus erythematosus; APS, antiphospholipid syndrome; CVID, common variable immune deficiency; CLL, chronic lymphocytic leukemia; APLS, autoimmune lymphoproliferative syndrome; post-tx, post-bone marrow or solid organ transplantation

Close modal

Distinguishing primary from secondary ITP may be problematic. Patients deemed to have primary ITP on clinical grounds are often found to have antinuclear antibodies, antiphospholipid antibodies, antithyroid antibodies, or a positive direct red-cell antiglobulin test.1,26  Nevertheless, it is uncommon for patients who present with primary ITP to develop another clinically overt autoimmune disease over time, with the exception of those with antithyroid antibodies.

There are no observational studies of untreated ITP in adults, because patients generally present with bleeding that requires intervention. The long-term outcomes in adults treated with initial daily oral prednisone supplemented with intravenous immune globulin or intravenous anti-(Rh)D are difficult to ascertain, with estimates of patients who do not require additional therapy ranging from 5% to 40%. Even patients who have required intensive therapy for years may show improvement over time.27,28  In general, however, the incidence of remission lessens as the duration of disease increases. Therefore, the international working group recommends subdividing ITP based on disease duration using the terms “newly diagnosed” for disease less than 3 months from diagnosis, “persistent” for disease lasting 3 to 12 months, and “chronic” to designate a more protracted course.2,3 

Principles

Treatment of ITP should be individualized. The traditional goal of therapy is to provide a hemostatic platelet count of 30 × 109/L or more for most patients, while minimizing toxicity. This approach to management is predicated on three assumptions: 1) the platelet count is a reliable surrogate marker of bleeding risk, 2) medical intervention does not alter the natural history of primary ITP, and 3) the burden of disease and its impact on quality of life are adequately captured by bleeding and drug toxicity. Each of these assumptions can be justified and each can be questioned.

Platelet Count

Evidence suggests that platelet count is predictive of serious bleeding in ITP. For example, in the absence of a hemostatic comorbidity, trauma, or surgery, intracranial hemorrhage is extremely rare in patients with platelet counts above 20 × 109/L, as is major hemorrhage in general when the platelet count exceeds 20 to 30 × 109/L. 29 

On the other hand, a platelet count of 30 × 109/L may be suboptimal for some patients. Recently published recommendations from an international consensus panel state that: “Relevant factors that contribute to management decisions include the extent of bleeding, comorbidities predisposing to bleeding, complications of specific therapies, activity and lifestyle, tolerance of side effects, potential interventions that may cause bleeding, accessibility of care, patient expectations, and patient need for non-ITP medications that may create a bleeding risk.” Bleeding risk is higher in older patients and those with a prior history of bleeding.3 

Remission

The potential for B- and T-epitope30  migration over time, leading to increased production of higher-affinity, platelet-specific antibodies creates a rationale for early intervention with immunosuppressive agents31  at the time of diagnosis. Recent studies using this approach appear to have challenged the concept that the natural history of ITP in adults is unalterable (see “First-line Therapy for Newly Diagnosed Patients” section below).

Quality of Life

The international consensus panel guidelines recognize the importance of patient preference.3  It is increasingly recognized that some patients with ITP experience disabling fatigue, apprehension of bleeding, restricted activities of daily living, withdrawal from important professional and recreational activities, and a poor quality of life.32,33  Two recently licensed TRAs, romiplostim and eltrombopag (see “TRAs” section below), have been shown to improve quality of life in randomized, controlled trials of adults with chronic primary ITP.21,22 

Who to Treat

Treatment is rarely indicated at platelet counts above 30 × 109/L in the absence of platelet dysfunction or another hemostatic defect, surgery, trauma, concomitant use of anticoagulants, or in those whose lifestyle predisposes to injury.3  Consensus guidelines for target platelet counts during surgery in patients with ITP have been established by the international consensus panel (Table 3), though these are based largely on experience rather than formal study, and treatment must be individualized.

Corticosteroids, supplemented with either intravenous immune globulin or anti-Rh(D) as needed, are used to stop bleeding and increase the platelet count to above 30 to 50 × 109/L in newly diagnosed patients (Table 4). Although these agents are generally safe and well-tolerated, anti-Rh(D) administration is, on rare occasions, complicated by severe intravascular hemolysis, disseminated intravascular coagulation, and acute renal failure, and should therefore be avoided in patients with evidence of underlying hemolysis or a positive direct antiglobulin test not due to prior therapy.34  Several uncontrolled studies suggest that bolus oral dexamethasone for one to four cycles as an initial therapy increases response rates and prolongs remission duration without additional toxicity. In one trial, a single course of dexamethasone 40 mg/d for 4 d (equivalent to ∼400 mg/d prednisone) produced a sustained response in 50% of newly diagnosed adults.35  In another study, dexamethasone given every 14 d for four cycles generated an 86% response rate, with 74% of patients achieving complete remission for a median of 8 months.36  Randomized, controlled trials are needed to validate the superiority of aggressive up-front therapy over prednisone. In one recent trial, patients randomized to an intravenous anti-CD20 antibody (rituximab) and dexamethasone as an initial treatment showed higher response rates and duration than those treated with a single course of dexamethasone.31  Longer follow-up and controlled studies using optimal treatment regimes will be required to place such intense intervention at disease onset in proper perspective.

ITP patients should be hospitalized if they have: 1) internal bleeding or profound mucocutaneous bleeding, 2) platelet counts under 10 × 109/L and a history of significant bleeding or noncompliance, and 3) platelet counts of 10 to 20 × 109/L in whom responsiveness to therapy has not been established (particularly if difficulty with immediate follow-up is anticipated). Most other ITP patients can be treated as outpatients. We initiate urgent treatment with corticosteroids in combination with either intravenous immune globulin or anti-Rh(D) in Rh-positive individuals who have not undergone splenectomy and do not have a positive direct antiglobulin test, until the platelet count exceeds 30 × 109/L and bleeding, if present, stops.3,29  Platelet transfusions are often useful in the setting of life- or organ-threatening bleeding or following head trauma. We combine intravenous immune globulin and anti-Rh(D), which act through different IgG-Fcγ receptors, with vincristine and methylprednisolone in patients failing initial therapy.37  Recombinant factor VIIa is reserved for the rare patient unresponsive to other modalities if an immediate hemostatic response is necessary (e.g., intracranial hemorrhage). We use ε-aminocaproic acid or tranexamic acid to help control oral bleeding or epistaxis, topical thrombin and fibrin glue to manage dental extractions, and progestational agents to manage menorrhagia. It is also important to initiate general measures to reduce the risk of bleeding, such as cessation of drugs that impair platelet function and control of blood pressure.

In light of the cumulative toxicities associated with prolonged corticosteroid use, minimizing steroid exposure once a response with first-line therapy occurs is a priority. Alternative modalities should be instituted in the absence of a robust response by one month or once significant steroid-related toxicity supervenes3,29  (Table 5). Occasional patients respond to extremely low levels of corticosteroids and fewer still can be treated on an every-other-day schedule. Danazol, either alone or in combination with azathioprine, and dapsone have been used as steroid-sparing agents.29  However, the next option for most patients involves splenectomy, rituximab, or TRA therapy.

Splenectomy

For decades, splenectomy has been the standard management of ITP patients unresponsive to or intolerant of prednisone. Two-thirds of patients attain a durable long-term remission, and others attain a partial response that may allow for a reduction in the use of rescue therapy.38  Even a substantial fraction of patients who do not respond to splenectomy initially may ultimately attain a hemostatic platelet count without supportive treatment.39  Morbidity and mortality of laparoscopic splenectomy are low in the hands of, experienced surgeons,40  and the incidence of overwhelming sepsis is reduced when recommended vaccination protocols are followed and antibiotics are initiated at the first sign of a systemic febrile illness.41  Response rates are lower in older patients, but there are no reliable predictors of response, with the possible exception of 111In-labeling of platelets, which is not widely available. Recently, concerns have been raised about late complications, including atherosclerosis, pulmonary hypertension, and defects in immune surveillance.38,40  Fewer physicians recommend and fewer patients now opt for splenectomy as the initial second-line form of management, although this approach by far offers the highest chance for remission and remains cost-effective.

Anti-CD20

A single course of rituximab (375 mg/m2 weekly for 4 weeks) induces a complete remission (here defined as a platelet count above 150 × 109/L) in approximately 40% of patients at 1 year,42  one-third after 2 years,43  and 15% to 20% at 5 years.3  An initial rise in platelet count often occurs within 1 to 2 weeks, suggesting an effect on platelet clearance, but more durable responses may not be observed until several months after treatment. Many patients who achieve an initial complete remission and subsequently relapse respond to retreatment. Partial responders, in contrast, often relapse within 1 year and generally do not enjoy sustained responses to retreatment. In a small, uncontrolled study, lower doses (100 mg weekly for 4 weeks) were almost as effective, although the time to response was prolonged.44  Severe side effects from infusion are uncommon, but may include respiratory distress. Rituximab is contraindicated in patients with active hepatitis B. Protracted abnormalities in B- and T-cell repertoires and impaired response to carbohydrate-based vaccine antigens have been noted, though their clinical significance is uncertain. Over 50 cases of progressive multifocal leukoencephalopathy have been reported in HIV-negative patients treated with rituximab, one of whom had ITP.45  The contribution of rituximab to the acquisition of progressive multifocal leukoencephalopathy in these heavily pretreated patients is unclear. Additional long-term safety data are required to quantify this risk and to identify risk factors for the development of this progressive and generally fatal toxicity. Other anti-CD20 antibodies are in development or clinical trials.

TRAs

Two TRAs, romiplostim and eltrombopag, have been approved by the Food and Drug Administration (FDA) for use in patients with primary ITP who require treatment after an initial course of corticosteroids. In some parts of the world, approval is restricted to patients needing therapy after splenectomy.

Romiplostim is a “peptibody” composed of four identical peptides that bind to the thrombopoietin receptor cMPL fused to an Fc fragment to prolong its half-life. It is administered weekly as a subcutaneous injection (1–10 μg/kg). In two parallel, placebo-controlled, double-blind randomized phase III trials, the study drug was given to 63 splenectomized and 62 non-splenectomized patients for 6 months. The primary efficacy end point, a platelet count of 50 × 109/L or above for at least 6 of the last 8 weeks of the study in the absence of rescue therapy, was achieved in 61% of non-splenectomized patients and in 38% of splenectomized individuals receiving romiplostim, and in only 1 of 42 subjects receiving placebo.22  Many romiplostim-treated patients reduced or discontinued concurrent ITP therapy, primarily corticosteroids, and reported improved quality of life.32  In an ongoing open-label extension study, most patients, some approaching 5.5 years of treatment with romiplostim, have sustained their platelet response.23 

Eltrombopag is formulated for oral administration at a dose of 25 to 75 mg/d. It must be taken 1 h before or 2 h after a meal, and should not be taken within 4 h of medications or products containing polyvalent cations such as antacids, dairy products, or mineral supplements. Initial dosage is reduced by 50% in patients of southeast Asian origin. The dose of rosuvastatin or other substrates of the OATP1B1 transporter, which is inhibited by eltrombopag, may require adjustment. Efficacy similar to romiplostim has been observed in clinical trials of eltrombopag. In a phase III study lasting 6 weeks, 114 subjects were randomized to receive eltrombopag or placebo. The primary end point, a platelet count of 50 × 109/L or above at week 6, was achieved in 59% and 16% of eltrombopag-treated and placebo-treated subjects, respectively.21  Patients receiving eltrombopag experienced less bleeding, less need for rescue medication, and a reduction in concomitant treatments. Similar findings were documented in a 6-month phase III trial.46  Sustained responses of up to 2 years in an ongoing open-label extension study have been reported.47 

Romiplostim and eltrombopag are generally well tolerated. Increased bone marrow reticulin has been observed in a few patients within 1 year of initiating TRA therapy. However, loss of response associated with evidence of a myelophthistic picture is rare and appears to be reversible in most cases. Additional long-term studies are needed to elucidate the incidence and natural history of TRA-induced bone marrow fibrosis and to compare these findings with the effects of other ITP therapies on bone marrow histology.48 

Rebound thrombocytopenia to levels below those at the onset of treatment was noted in approximately 10% of patients who discontinued either romiplostim or eltrombopag in clinical trials. Gradual withdrawal of TRAs, careful surveillance, and possibly preemptive introduction of concomitant ITP medications may prevent or ameliorate this toxicity.

To date, there is no compelling evidence that either TRA increases thromboembolic complications in patients with ITP. In a pooled analysis of all studies of romiplostim, the incidence of thrombosis did not differ among those treated with study drug and those receiving placebo (8 vs. 10 events/100 patient-years, respectively).49  In a pooled analysis of studies of eltrombopag in ITP, 17 eltrombopag-treated patients suffered thrombotic complications over 377 patient-years of exposure. Although no events were documented in placebo-treated subjects, the exposure of this cohort was limited to only 26 patient-years.50  Most TRA-associated thromboembolic events have occurred in patients with preexisting atherosclerosis or thrombotic risk factors, often in the setting of a low or normal platelet count. In light of recent evidence that eltrombopag may increase the risk of venous thrombosis in patients with hepatitis C, and that ITP itself may be prothrombotic in some patients,51  additional study of the incidence of TRA-associated thrombosis and identification of potential risk factors is warranted.

Thus far, data regarding the risk of leukemogenesis with TRA therapy are reassuring. In the controlled trials of romiplostim and eltrombopag, the incidence of hematologic neoplasm was low and similar in the treatment and placebo groups.21,22,46  In studies of patients with myelodysplastic syndrome-associated thrombocytopenia, romiplostim was associated with a transient and reversible rise in circulating blasts in a minority of patients, but the rate of leukemic transformation did not differ between romiplostim- and placebo-treated subjects.52 

Hepatobiliary laboratory abnormalities were detected in 13% of eltrombopag-treated patients, prompting a black-box warning that calls for regular monitoring of liver function tests. Cataract formation was observed in preclinical testing of eltrombopag in juvenile rodents at doses several times higher than the human clinical exposure. Until more is known regarding the risk of cataract development in humans at clinically approved doses of eltrombopag, periodic ophthalmic examinations are advisable.

Several immunosuppressive agents alone or in combination have shown some efficacy in small, uncontrolled studies; these include azathioprine, cyclophosphamide, mycophenylate mofetil, and cyclosporine3,53  (Table 5). However, because of a less favorable safety profile, these agents are generally reserved for patients unresponsive to or ineligible for the aforementioned first- and second-line treatment options. Vinca alkaloids are used infrequently and hematopoietic stem-cell transplantation is reserved for extreme circumstances. New agents that affect antibody production, platelet production, or clearance are in development.

ITP is a syndrome of various disorders that have in common immune-mediated thrombocytopenia, but that differ in pathogenesis, natural history, comorbidities, and responsiveness to therapy. As our understanding of disease pathogenesis grows, the term “primary ITP” will be confined to a decreasing proportion of patients in whom a potential etiology has not been identified and pathogenic pathways have not been elucidated.1  The contribution of impaired platelet poiesis remains uncertain and cannot as yet be monitored clinically, but TRAs appear capable of overriding antibody-mediated platelet clearance in most patients. It may be possible to use high-throughput screening to clone autoantibodies and identify epitopes to search for external antigens that predispose to platelet antibody formation for the purposes of developing rational therapies. Identification of the responsible B- and T-cell clones would also enhance drug monitoring and might lead to more selective therapy.

Approaches to the management of ITP remain in flux. In the absence of predictors of bleeding or biomarkers of pathogenesis or response, platelet counts remain the surrogate marker of choice, however imprecise. The international working group report notes that in patients with persistent ITP “…spontaneous remission may still occur and aggressive interventions might be deferred, if possible.” This recommendation is being challenged by the high complete remission rates observed in studies of up-front aggressive therapy, although the long-term benefit and toxicity of such approaches remain to be determined through controlled studies with long-term follow-up.

With regard to second-line therapy, a minimalist approach based on bleeding and a threshold platelet count of 30 × 109/L using prednisone followed by splenectomy is cost-effective and has been proven to be clinically effective in terms of preventing death from hemorrhage. However, the toxicity of corticosteroids and concerns about the long-term effects of splenectomy have affected patient and physician preferences and are associated with impaired quality of life in non-responders. Rituximab has a favorable toxicity profile, but the effect of repetitive cycles of immunosuppressive therapy has not been assessed in large numbers of patients or with follow-up comparable to splenectomy. TRAs pose an exciting new treatment option and a new set of challenges with respect to duration of treatment, cost, and need for long-term safety studies. Newer agents that affect antibody production, platelet production, and clearance are in development. The last few years have been marked by tremendous advances in our understanding and management of ITP; fortunately, it appears that this is likely to continue.

Conflict-of-interest disclosure: DBC has consulted for Glaxo-Smith-Kline and Amgen. Off-label drug use: Only intravenous immune globulin G, anti-Rh(D), romiplostim, and eltromopag are approved for the treatment of ITP. All other agents for the management of ITP discussed in this chapter are off-label.

Adam Cuker, MD, MS, Hospital of the University of Pennsylvania, 3 Dulles, 3400 Spruce Street, Philadelphia, PA 19104; Phone: (215) 615-8015; Fax: (215) 615-6599; e-mail: adam.cuker@uphs.upenn.edu

1
Cines
DB
Bussel
JB
Liebman
HA
Luning Prak
ET
The ITP syndrome: pathogenic and clinical diversity
Blood
2009
113
6511
6521
2
Rodeghiero
F
Stasi
R
Gernsheimer
T
et al
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
Blood
2009
113
2386
2393
3
Provan
D
Stasi
R
Newland
AC
et al
International consensus report on the investigation and management of primary immune thrombocytopenia
Blood
2010
115
168
186
4
Stasi
R
Amadori
S
Osborn
J
Newland
AC
Provan
D
Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia
PLoS Med
2006
3
e24
5
Marieke Schoonen
W
Kucera
G
Coalson
J
et al
Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database
Br J Haematol
2009
145
235
244
6
Abrahamson
PE
Hall
SA
Feudjo-Tepie
M
Mitrani-Gold
FS
Logie
J
The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review
Eur J Haematol
2009
83
83
89
7
Segal
JB
Powe
NR
Prevalence of immune thrombocytopenia: analyses of administrative data
J Thromb Haemost
2006
4
2377
2383
8
Rischewski
JR
Imbach
P
Paulussen
M
Kuhne
T
Idiopathic thrombocytopenic purpura (ITP): is there a genetic predisposition?
Pediatr Blood Cancer
2006
47
678
680
9
Coopamah
MD
Garvey
MB
Freedman
J
Semple
JW
Cellular immune mechanisms in autoimmune thrombocytopenic purpura: An update
Transfus Med Rev
2003
17
69
80
10
Yu
J
Heck
S
Patel
V
et al
Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura
Blood
2008
112
1325
1328
11
Emmerich
F
Bal
G
Barakat
A
et al
High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura
Br J Haematol
2007
136
309
314
12
Craig
VJ
Arnold
I
Gerke
C
et al
Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins
Blood
2010
115
581
591
13
Li
Z
Nardi
MA
Karpatkin
S
Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia
Blood
2005
106
572
576
14
Zhang
W
Nardi
MA
Borkowsky
W
Li
Z
Karpatkin
S
Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia
Blood
2009
113
3887
3888
15
Takahashi
T
Yujiri
T
Shinohara
K
et al
Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura
Br J Hematol
2004
124
91
96
16
Stasi
R
Sarpatwari
A
Segal
JB
et al
Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review
Blood
2009
113
1231
1240
17
Ballem
PJ
Belzberg
A
Devine
DV
et al
Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection
N Engl J Med
1992
327
1779
1784
18
Houwerzijl
EJ
Blom
NR
van der Want
JJL
et al
Ultrastructural study shows morphological features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura
Blood
2003
103
500
506
19
McMillan
R
Wang
L
Tomer
A
Nichol
J
Pistillo
J
Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP
Blood
2004
103
1364
1369
20
Olsson
B
Ridell
B
Carlsson
L
Jacobsson
S
Wadenvik
H
Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1
Blood
2008
112
1078
1084
21
Bussel
JB
Provan
D
Shamsi
T
et al
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
Lancet
2009
373
641
648
22
Kuter
DJ
Bussel
JB
Lyons
RM
et al
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
Lancet
2008
371
395
403
23
Bussel
JB
Kuter
DJ
Pullarkat
V
Lyons
RM
Guo
M
Nichol
JL
Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP
Blood
2009
113
2161
2171
24
Nardi
M
Tomlinson
S
Greco
MA
Karpatkin
S
Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia
Cell
2001
106
551
561
25
Olsson
B
Andersson
P-O
Jernas
M
Jacobsson
S
Carlsson
LMS
Wadenvik
H
T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura
Nat Med
2003
9
1123
1124
26
Cines
DB
Liebman
H
Stasi
R
Pathobiology of secondary immune thrombocytopenia
Semin Hematol
2009
46
S2
14
27
Cooper
N
Woloski
BM
Fodero
EM
et al
Does treatment with intermittent infusions of inravenus anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenia to avoid splenectomy?
Blood
2002
99
1922
1927
28
McMillan
R
Durette
C
Long-term outcomes in adults with chronic ITP after splenectomy failure
Blood
2004
104
956
960
29
Cines
DB
Bussel
JB
How I treat idiopathic thrombocytopenic purpura (ITP)
Blood
2005
106
2244
2251
30
Sukati
H
Watson
HG
Urbaniak
SJ
Barker
RN
Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune thrombocytopenic purpura
Blood
2007
109
4528
4538
31
Zaja
F
Baccarani
M
Mazza
P
et al
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia
Blood
2010
115
2755
2762
32
George
JN
Mathias
SD
Go
RS
et al
Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials
Br J Haematol
2009
144
409
415
33
McMillan
R
Bussel
JB
George
JN
Lalla
D
Nichol
JL
Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura
Am J Hematol
2008
83
150
154
34
Tarantino
MD
Bussel
JB
Cines
DB
et al
A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP)
Blood
2005
106
1532
1537
35
Cheng
Y
Wong
RSM
Soo
YOY
et al
Initial treatment of immune thrombocyopenic purpura with high-dose dexamethasone
N Engl J Med
2003
349
831
836
36
Mazzucconi
MG
Fazi
P
Bernasconi
S
et al
Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience
Blood
2007
109
1401
1407
37
Boruchov
DM
Gururangan
S
Driscoll
MC
Bussel
JB
Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP)
Blood
2007
110
3526
3531
38
Kojouri
K
Vesely
SK
Terrell
DR
George
JN
Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications
Blood
2004
104
2623
2634
39
McMillan
R
Durette
C
Long-term outcomes in adults with chronic ITP after splenectomy failure
Blood
2004
8
15
104
4
956
60
40
Crary
SE
Buchanan
GR
Vascular complications after splenectomy for hematologic disorders
Blood
2009
114
2861
2868
41
Davies
JM
Barnes
R
Milligan
D
Update of guidelines for the prevention and treatment of infections in patients with an absent or dysfunctional spleen
Clin Med
2002
2
440
443
42
Arnold
DM
Dentali
F
Crowther
MA
et al
Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura
Ann Intern Med
2007
146
25
33
43
Godeau
B
Porcher
R
Fain
O
et al
Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study
Blood
2008
112
999
1004
44
Zaja
F
Battista
ML
Pirrotta
MT
et al
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura
Haematologica
2008
93
930
933
45
Carson
KR
Evens
AM
Richey
EA
et al
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Blood
2009
113
4834
4840
46
Cheng
G
Saleh
MN
Bussel
JB
et al
Oral eltrombopag for the long-term treatment of patients with chronic idiopathic thrombocytopenic purpura: results of a phase III, double-blind, placebo-controlled study (RAISE) [Abstract]
Blood
2008
112
400
47
Saleh
MN
Bussel
JB
Cheng
G
et al
Long-term treatment of chronic immune thrombocytopenic purpura with oral eltrombopag: Results from the EXTEND study [Abstract]
Blood
2009
114
682
48
Cuker
A
Chiang
EY
Cines
DB
Safety of the thrombopoiesis-stimulating agents for the treatment of immune thrombocytopenia
Curr Drug Saf
2010
5
171
181
49
Liebman
H
Henry
D
Lefrere
F
et al
Long-term safety profile of romiplostim in patients with chronic immune thrombocytopenia (ITP)
Blood
2008
112
Abstract 3415
50
Bussel
J
Cheng
G
Saleh
M
Vasey
S
Aivado
M
Brainsky
A
Thromboembolic events observed in eltrombopag clinical trials in chronic immune thrombocytopenic purpura [Abstract]
Blood
2009
114
2423
51
Aledort
LM
Hayward
CP
Chen
MG
Nichol
JL
Bussel
J
Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies
Am J Hematol
2004
76
205
213
52
Cuker
A
Toxicities of the thrombopoietic growth factors
Semin Hematol
2010
47
289
298
53
Arnold
DM
Nazi
I
Santos
A
et al
Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura
Blood
2010
115
29
31